| |
Release Date
12/6/2012
Expiration Date
12/6/2013
This program has expired. CME credit is no longer available. |
|
|
| |
|
|
| |
 |
Nezam Afdhal, MD
Beth Israel Deaconess
Medical Center
Boston, MA
|
|
| |
 |
|
| |
|
|
| |
 |
Kim Brown, MD
Henry Ford Hospital
Detroit, MI |
|
| |
|
|
| |
|
|
| |
 |
Jordan Feld, MD
Toronto Western Hospital
Liver Center
Toronto, Canada |
|
| |
|
|
| |
|
|
| |
 |
Michael Fried, MD
University of North Carolina
Chapel Hill, NC |
|
| |
|
|
| |
|
|
| |
 |
Ira Jacobson, MD
Weill Cornell Medical College
New York, NY |
|
| |
|
|
| |
|
|
| |
|
|
| |
 |
|
| |
|
|
| |
|
| |
|
|
|
|
|
Nezam Afdhal, MD
Beth Israel Deaconess Medical Center
Boston, MA |
Nezam H. Afdhal, MD, is Chief of Hepatology and director of the Liver Center at Beth Israel Deaconess Medical Center in Boston, Massachusetts. He is also Professor of Medicine at Harvard Medical School. Dr. Afdhal received his medical degree in 1981 from the Royal College of Surgeons in Ireland and did fellowship training at University College Dublin and at Boston University School of Medicine.
Dr. Afdhal’s clinical expertise focuses on the management of the complications of liver disease, including cirrhosis and portal hypertension. He is the director of a clinical trials group focusing on novel treatments of hepatitis B and C, liver fibrosis, and NASH. Additional research interests include basic and translational research in gallstone disease, liver cancer, and liver fibrosis. His research is funded by multiple NIH, industry, and foundation grants.
Dr. Afdhal has served on multiple state and national advisory boards for liver disease. He has also served on the Editorial Boards of and as a reviewer for multiple journals. Dr. Afdhal has published more than 180 papers in journals such as New England Journal of Medicine, Gastroenterology, Hepatology, Gut, and Journal of Hepatology, as well as 30 book chapters and 2 books. He is the editor for Journal of Viral Hepatitis, and has spoken nationally and internationally on chronic liver disease. His many awards include the American Liver Foundation Award for Excellence, a Fullbright Scholarship, and the Mitchell Lectureship of the Royal College of Physicians. He is a member of the American Gastroenterological Association, the American Association for the Study of Liver Diseases, and the European Association for the Study of the Liver.
Speaker Disclosure:
Nezam Afdhal, MD, has disclosed that he has received grants for clinical research from Schering Plough/Merck, Novartis, Glaxo Smith Kline, Echosens, Vertex, Gilead, Quest, Pharmasett, and Abbott. He has served as a consultant for and has participated in advisory boards for Gilead, Echosens, Glaxo Smith Kline, Vertex, Novartis, Boehringer Ingelheim, Ligand, Springbank, Medgenics, and Schering/Merck-Managed by HMS and BIDMC. He is a stockholder for Springbank and Medgenics.
|
|
